Raised HDL cholesterol in Fabry disease: response to enzyme replacement therapy.
Fabry disease patients have increased risk of vascular disease despite cardioprotective increased HDL-cholesterol. Enzyme therapy does not significantly alter the lipid profile in the short term.
Cartwright
D J
DJ
Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, London, UK.
Cole
A L
AL
Cousins
A J
AJ
Lee
P J
PJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D000795:Fabry Disease / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood* / Q000209:etiology*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012727:Sex Characteristics; D000519:alpha-Galactosidase / Q000627:therapeutic use*
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D000519:alpha-Galactosidase